Press release
Pheochromocytomas and Paragangliomas (PCPG) Market is projected to reach USD 1.24 billion by 2034
Pheochromocytomas and Paragangliomas
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71616
Pheochromocytomas (tumors of the adrenal medulla) and paragangliomas (extra-adrenal neuroendocrine tumors) can cause excessive catecholamine secretion, leading to hypertension and multisystem complications. Growing awareness of hereditary syndromes-such as MEN2, VHL, NF1, and SDH mutations-has led to earlier diagnosis and risk-based screening in high-prevalence families.
The market is witnessing significant development in radiopharmaceuticals, peptide receptor radionuclide therapy (PRRT), small-molecule inhibitors, and personalized medicine approaches. Increasing availability of advanced imaging modalities such as PET-CT, MIBG scintigraphy, and MRI further enhances early tumor localization and staging.
Key Market Highlights
• 2024 Market Size: USD 650 million
• 2034 Forecast: USD 1.24 billion
• CAGR (2025-2034): 6.7%
• Largest Region: North America
• Fastest-Growing Region: Asia Pacific
Market Drivers
1. Rising Diagnostic Capabilities for Rare Endocrine Tumors
Growth in clinical awareness, genetic testing, and advanced imaging has increased the detection rate of PCPG tumors, including early-stage and asymptomatic cases.
2. Advancements in Targeted Therapy & Precision Medicine
Therapies targeting specific mutations (e.g., SDHB, RET, VHL) and radiolabeled agents such as ^131I-MIBG and PRRT are expanding the treatment landscape.
3. Increasing Prevalence of Hereditary Cancer Syndromes
Family-based screening programs and genetic counseling promote early diagnosis and proactive management.
4. Growing Use of Nuclear Medicine & Radiopharmaceuticals
PET tracers (DOTATATE, FDG, DOPA) and targeted radionuclide treatments are becoming central in PCPG treatment pathways.
5. Expansion of Rare Disease Funding & Research
Global initiatives encouraging orphan drug development are accelerating clinical trials for PCPG patients.
Market Restraints
• Limited curative options for metastatic disease
• High cost of genetic testing and nuclear medicine imaging
• Shortage of specialized treatment centers
• Potential toxicity associated with radionuclide therapies
• Low patient numbers limiting large-scale clinical trials
Market Opportunities
1. Development of Next-Generation Radiopharmaceuticals
Improved precision imaging and targeted radionuclide therapies offer substantial commercial potential.
2. Genomic and Biomarker-Driven Treatment
Mutational profiling can guide personalized treatments and improve therapeutic response.
3. Expansion of Nuclear Medicine Infrastructure in Emerging Markets
Improving PET/CT and gamma camera access expands diagnosis and treatment reach.
4. Combination Therapies
Synergistic use of PRRT, targeted inhibitors, and immunotherapy is showing promising results.
5. Growth in Tele-endocrinology & Remote Monitoring
Digital follow-up tools support long-term management of hereditary PCPG patients.
Segmentation Overview
By Treatment Type
• Targeted therapy (kinase inhibitors, RET inhibitors, SDH-targeted agents)
• Radiopharmaceutical therapy (^131I-MIBG, PRRT)
• Chemotherapy
• Surgical resection
• Hormonal and symptomatic management
By Diagnostic Method
• PET/CT imaging (DOTATATE, FDG, DOPA)
• MIBG scintigraphy
• MRI & CT imaging
• Biochemical tests (catecholamines, metanephrines)
• Genetic testing
By Tumor Type
• Pheochromocytoma
• Paraganglioma
o Head & neck
o Thoracic
o Abdominal
o Pelvic
By End User
• Hospitals
• Oncology and endocrinology centers
• Nuclear medicine centers
• Research institutes
Explore Full Report here: https://exactitudeconsultancy.com/reports/71616/pheochromocytomas-and-paragangliomas-pcpg-market
Regional Insights
North America - Largest Market
Advanced diagnostic infrastructure, wide adoption of genetic testing, strong availability of nuclear medicine, and extensive rare cancer research support regional leadership.
Europe - High Adoption of PRRT & Genetic Screening
Strong regulatory support for orphan drugs and widespread use of radionuclide therapies drive growth.
Asia Pacific - Fastest Growing Market
Increasing awareness of hereditary cancer syndromes, rising investments in molecular diagnostics, and improving nuclear medicine capacity fuel market expansion.
Latin America & Middle East/Africa - Emerging Regions
Gradual improvements in oncology systems and access to imaging technologies create long-term growth opportunities.
Competitive Landscape
Key companies operating in the PCPG market include:
• Novartis (Lutathera, radiopharmaceuticals)
• Progenics Pharmaceuticals
• GE Healthcare
• Siemens Healthineers
• Bayer
• Pfizer
• Merck
• Thermo Fisher Scientific
• PerkinElmer
• Advanced Accelerator Applications
• Philips Healthcare
These companies focus on radiopharmaceutical solutions, targeted inhibitors, imaging technologies, and precision diagnostic tools.
Recent Market Developments
• Advancements in PRRT for metastatic PCPG
• Progress in RET and other mutation-specific inhibitors
• Launch of improved PET tracers for early tumor localization
• Increased genetic screening for hereditary paraganglioma syndromes
• Expansion of global rare disease drug pipelines
Future Outlook (2025-2034)
The PCPG market is expected to evolve toward:
• Broader adoption of precision oncology
• Increased use of PRRT, targeted therapy, and molecular imaging
• Expansion of hereditary screening for early intervention
• Greater integration of artificial intelligence in nuclear imaging
• Improved access to orphan drugs in emerging markets
With rapid developments in nuclear medicine, genetics, and targeted therapeutics, the market is set to grow from USD 650 million in 2024 to USD 1.24 billion by 2034, demonstrating strong long-term commercial potential.
This report is also available in the following languages : Japanese (褐色細胞腫および傍神経節腫(PCPG)市場), Korean (갈색세포종 및 부신경절종(PCPG) 시장), Chinese (嗜铬细胞瘤和副神经节瘤(PCPG)市场), French (Marché des phéochromocytomes et des paragangliomes (PCPG)), German (Markt für Phäochromozytome und Paragangliome (PCPG)), and Italian (Mercato dei feocromocitomi e dei paragangliomi (PCPG)), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/71616
Our More Reports:
Pheochromocytoma Market
https://exactitudeconsultancy.com/reports/71562/pheochromocytoma-market
U.S. Pheochromocytoma Market
https://exactitudeconsultancy.com/reports/50836/u-s-pheochromocytoma-market
Paraganglioma Market
https://exactitudeconsultancy.com/reports/71558/paraganglioma-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pheochromocytomas and Paragangliomas (PCPG) Market is projected to reach USD 1.24 billion by 2034 here
News-ID: 4306944 • Views: …
More Releases from Exactitude Consultancy
Cold Planer Market Sees Consistent Growth Supported by Global Road Rehabilitatio …
The global cold planer market is experiencing steady growth as governments and private contractors increase spending on road rehabilitation, resurfacing, and infrastructure modernization. Cold planers, also known as milling machines, are widely used to remove damaged asphalt and concrete surfaces efficiently, supporting sustainable road construction practices.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68250
Key Market Highlights
• Increasing focus on road maintenance and resurfacing projects
• Growing demand for efficient and precision milling…
Credit Management Software Market Accelerates as Organizations Focus on Risk Mit …
The global credit management software market is witnessing robust growth as organizations across industries adopt digital solutions to manage credit risk, improve receivables performance, and strengthen financial controls. Credit management software enables businesses to automate credit scoring, monitor customer creditworthiness, and streamline collections processes.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68248
Key Market Highlights
• Growing adoption of automated credit risk assessment tools
• Increasing focus on working capital and cash flow management
• Integration…
Session Border Controller Market Expands Rapidly as Enterprises and Telecom Oper …
The global session border controller (SBC) market is experiencing strong growth as telecom operators and enterprises increasingly deploy SBC solutions to secure, manage, and optimize real-time IP communications. SBCs play a critical role in protecting voice over IP (VoIP), unified communications (UC), and multimedia sessions from cyber threats while ensuring interoperability and quality of service.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68246
Key Market Highlights
• Growing adoption of VoIP and…
Biofuel Market Including E-Methane and Sustainable Aviation Fuel Gains Strong Tr …
The global biofuel market, encompassing e-methane, sustainable aviation fuel (SAF), and other advanced biofuels, is witnessing robust growth as governments and industries intensify efforts to reduce carbon emissions and transition toward cleaner energy sources. These fuels play a critical role in achieving net-zero targets while enabling decarbonization of hard-to-abate sectors such as aviation, shipping, and heavy transportation.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68244
Key Market Highlights
• Rapid growth of…
More Releases for PCPG
Pheochromocytomas and Paragangliomas Market Size is projected to grow at a CAGR …
DelveInsight's "Pheochromocytomas and Paragangliomas Market Insights, Epidemiology, and Market Forecast 2034" report delivers an in-depth understanding of PCPG, historical and forecasted epidemiology as well as Pheochromocytomas and Paragangliomas therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Explore Pheochromocytomas/Paragangliomas Market Trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @ https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from Pheochromocytomas/Paragangliomas Market Report
• In November…
Pheochromocytomas and Paragangliomas Market to Grow Significantly by 2034, from …
The pheochromocytomas and paragangliomas market is poised for robust expansion, primarily driven by increasing diagnostic capabilities, rising disease awareness, and the anticipated launch of novel therapeutic options by key pheochromocytoma companies, such as Chimerix, Ohara Pharmaceutical, Merck, Novartis, Perspective Therapeutics, and others.
DelveInsight's "Pheochromocytomas and Paragangliomas Market Insights, Epidemiology, and Market Forecast - 2034"[https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr] report delivers comprehensive insights into Pheochromocytomas and Paragangliomas market, including historical and forecasted epidemiology, current treatment paradigms,…
Pheochromocytomas and Paragangliomas (PPGL) Market to Set Phenomenal Growth From …
Pheochromocytomas and Paragangliomas (PPGL) Market Outlook 2024-2034: Rising Awareness and Targeted Therapies Drive Growth
Introduction
Pheochromocytomas and paragangliomas (collectively known as PPGL or PCPG) are rare neuroendocrine tumors that originate from chromaffin cells in the adrenal medulla or extra-adrenal paraganglia. While pheochromocytomas arise in the adrenal glands, paragangliomas occur in various parts of the body including the abdomen, chest, and head-and-neck region.
Although rare, these tumors can be life-threatening if untreated, often associated…
Pheochromocytomas and Paragangliomas Market Forecast - Unlocking Rare Tumor Insi …
Pheochromocytomas and Paragangliomas (PCPG) are rare neuroendocrine tumors originating from chromaffin cells of the adrenal medulla and extra-adrenal paraganglia, respectively. While pheochromocytomas typically arise in the adrenal glands, paragangliomas can develop anywhere along the sympathetic and parasympathetic chains. Though generally benign, these tumors can secrete excess catecholamines, leading to severe cardiovascular complications such as hypertension, arrhythmias, and even stroke, if not diagnosed and managed promptly.
DelveInsight's comprehensive report, "Pheochromocytomas and Paragangliomas…
Pheochromocytomas and Paragangliomas Market to Grow Significantly by 2034, from …
The pheochromocytomas and paragangliomas market is poised for robust expansion, primarily driven by increasing diagnostic capabilities, rising disease awareness, and the anticipated launch of novel therapeutic options by key pheochromocytoma companies, such as Chimerix, Ohara Pharmaceutical, Merck, Novartis, Perspective Therapeutics, and others.
DelveInsight's "Pheochromocytomas and Paragangliomas Market Insights, Epidemiology, and Market Forecast - 2034 [https://www.delveinsight.com/report-store/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers comprehensive insights into Pheochromocytomas and Paragangliomas market, including historical and forecasted epidemiology, current treatment…
Pheochromocytomas and Paragangliomas Treatment Market Size in 7MM is expected to …
DelveInsight's "Pheochromocytomas and Paragangliomas Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Pheochromocytomas and Paragangliomas, historical and forecasted epidemiology as well as the Pheochromocytomas and Paragangliomas market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover which therapies are expected to grab the Pheochromocytomas and Paragangliomas Market Share @ Pheochromocytomas and Paragangliomas Market Outlook- https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the…
